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ABSTRACT
Objective: To investigate the effects of short-course nucleoside reverse transcriptase
inhibitor (Zidovudine, ZDW/AZT) on maternal immune responses and risk of infant
infection with HIV-1 among rural-based mothers in western Kenya.
Design: A prospective cohort study involving HIV-1 seropositive pregnant mothers and
their infants.
Subjects: One hundred and seven HIV-1 seropositive asymptomatic pregnant women
and their infants.
Methods: After informed consent, the women were enrolled at gestation age between
16-24 weeks. For cultural and economic reasons, all mothers were allowed to breast
feed their infants. Short-course antepartum regime of AZT was administered to all
mothers starting at 36 weeks gestation until start of labour. Maternal absolute CD4+
T cell subset assays were performed before 3rd trimester (about 36 weeks gestation)
and after a 4-week therapy of AZT (at least one month post-nuptially). Infant HIV-
1 status was determined by HIV-1 DNA polymerase chain reaction (PCR) on samples
sequentially taken at 1, 2, 3, 4, 6 and 9 months and confirmed by serology at 18 months
of age.
Interventions: Antepartum short-course orally administered AZT: 300mg twice-daily
starting at 36 weeks gestation until start of labour, 300mg at labour onset and 300mg
every three hours during labour until delivery.
Main Outcome Measures: Maternal CD4+ T cell counts before and after AZT treatment.
Determination of infant HIV-1 infection status.
Results: Among 107 women sampled, only 59 received full dose of AZT and thus qualified
for present analysis. Of these, 12 infected their children with HIV, while 47 did not.
Comparison of CD4+ T cells before and after AZT treatment scored a significant rise
in all mothers (P = 0.01). This increase in CD4+ T cells was not significant among
mothers who infected their infants with HIV-1 (P = 0.474). However, a significant rise
in CD4+ T cells following AZT therapy was observed only in mothers who did not
transmit HIV-1 to their infants (P=0.014).
Conclusion: These data suggest that a rise in the CD4+ T cell counts following short
AZT regimen, now widely in use in resource-weak countries, may be evidence of the
active suppression of the replication of HIV. However, further studies to examine the
multi-factorial effect of CD4+ lymphocytes and pregnancy on MTCT of HIV need to
be carried out to help fully explain the effect of AZT on immune response and whether
the CD4+T cell count can be used as a true test of immunological normalisation during
antiretroviral therapy.
INTRODUCTION
There is evidence that normal pregnancy and
pregnancy complicated with HIV infection is associated
with diminished immune responses(1-2). Reduced
maternal immunity, especially low CD4+ T cell count
has been associated with risk of having an infected
child(3-5). The World health Organisation (WHO)
estimates that of the 1.2 million children infected with
HIV world-wide, most of them live in Africa and
acquired their infection through mother-to-child
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transmission (MTCT)(6). The estimated risk of MTCT
in this region ranges from 25-30% (14-25% in the
developed world), the near universal practice of
breastfeeding explaining most of the difference(7-9).
Since 1994, when results of a large placebo-
controlled trial of AZT use during second and third
trimester in pregnant women and during the first weeks
of life, in the absence of breastfeeding, demonstrated
a significant reduction in MTCT (10-11). AZT has been
the reference prophylaxis for mother to child HIV
transmission(12-13). However, although AZT is said to
increase circulating CD4+ T lymphocytes during HIV
infection(14), its effects on immune reconstitution in
pregnancy are still not very well understood(15-16).
Any change in immune defences during pregnancy
could be particularly important for HIV-1 seropositive
women, in whom a significant degree of
immunodeficiency may already exist. In the present
analysis, we include CD4+ T cell counts before and
after AZT administration and correlate this with risk
of infant infection with HIV-1. This is done with the
objective of delineating the reconstitutive effect of
short-course AZT therapy on maternal immune response
(as measured by CD4+ T cell count) during HIV
infection in pregnancy and how this affects mother to
child transmission of HIV-1.
MATERIALS AND METHODS
Study Participants: The sample population consisted of
59 pregnant HIV seropositive mothers participating in a MTCT
study in four districts of western Kenya: Busia, Siaya, Bondo
and Kisumu. This sample population was part of the 107 HIV-
seropositive pregnant women who were participating in an
MTCT study in the above districts. Seven centres in the four
districts were used (Matayos, Khunyangu, Siaya, Usigu,
Kombewa, Chulaimbo and Nyahera) as clinical evaluation
centres. The sample population was aged 18 to 30 years, had
a mean parity of three and a baseline CD4+ T cell count of
499 cells/microlitre of blood (cells/µl) and were drawn from
the same socio-economic settings. After giving informed
consent, the mothers were enrolled at gestation age between
16 and 24 weeks from June to November 1998. Although the
mothers were counselled by trained counsellors on HIV and
its attendant risks of mother to infant transfer through
breastfeeding, a ban on the latter was not enforced. After
enrolment, the mothers were followed and evaluated at six and
eight months of pregnancy and at two and six months post
partum. During each visit, the same group of project clinicians
performed standardised physical examination for each mother
and administered a confidential questionnaire.
The infants born to these mothers were seen by the
project paediatrician after birth (at least within two calendar
weeks) and thereafter at ages 1, 2, 3, and 4 months and
subsequently every three months up to 18 months of age.
At every visit blood specimen were obtained from the infants.
Laboratory methods: HIV antibody tests: The HIV-1
antibody status of the mother and infant was determined by
testing serum/plasma with Particle Agglutination (PA Test,
Fujirebio, Japan) and anti-HIV-1/2 antibody ELISA
(EnzygnostR anti-HIV 1/2 Plus ELISA, Behring-Marburg,
Germany). Infant HIV-1 antibody status was confirmed using
samples collected from 18 months of age. Reactive samples
were confirmed by Western Blot (WB) assay (HIV Blot,
Genelab, Diagnostics, USA).
Diagnostic PCR: For early diagnosis of HIV-1 in
infants, we used nested PCR amplification of HIV-1 sequences
on DNA extracted from three consecutive PBMCs obtained
from children at age nine months. The quality of DNA was
checked by b -globin gene amplification. Nested PCR
employed the following primers: Envelope (ENV); ED3/14
and ED5/12, Polymerase (POL); HPOL 4320/4538, HPOL
4327/4481, Group Antigen (GAG); GAG-MZ13/14, MZ8/9.
Based on our in-house experience (not published), the
amplification of POL and ENV primers was used for early
diagnosis of HIV-1. The amplified products were then run
on a 2% NusieveR agarose gel stained with ethnidium
bromide and visualised by an electronic gel illuminator
(Toyobo-FASIII, Japan).
CD4+ T cell counts: Lymphocyte subset counts were
quantitated by standard flow cytometry procedures(17) using
monoclonal antibodies labelled with fluorochromes according
to instructions provided by the kit manufacturers (TritestTM
Becton-Dickinson, USA). Briefly, since CD4+ counts are
dependent on total lymphocyte count, WBC and lymphocyte
counts were performed on whole blood in EDTA using an
electronic blood cell counter (SysmexTM Electronic cell
counter, Japan). Aliquots of 50µl of whole blood in EDTA
were incubated with 3-colour fluorochrome-labelled
monoclonal antibodies (anti-CD3/45*PerP, anti-CD4*PE and
anti-CD8*FITC) (Becton-Dickinson, USA). After incubation
and lysis of red blood cells, flow cytometric analysis was
performed on FacscaliburR cytometer using an automatic
acquisition and analysis program (Multiset, Becton-Dickinson,
USA).
AZT administration: AZT was administered to HIV-1
confirmed mothers after informed consent and professional
counselling. The regimen given was a modification of the
short course ZDV recommended by the CDC for combination
with formula feeding(18). All women chose to breastfeed
their infants. The regimen involved the following:
(i). 1 AZT tablet (300mg) twice daily at 36 weeks of
gestation until onset of labour.
(ii). 1 AZT tablet (300 mg) at onset of labour.
(iii). 1 AZT tablet (300 mg) every three hours during labour
until delivery.
The same clinical officer/nurse team administered the
drug every week. RBC cell counts were used as a monitor
of side-effects, especially anaemia.
Ethical considerations: As part of our social contract
with the study population, the project continued to follow-
up all the children and especially HIV-infected children for
medical treatments for their ailments. To enhance sustainability
and avoid overdependence on the project for medical assistance,
the project initiated partnerships with the local health delivery
institutions where the study participants could join the on-
going cost-sharing program for medical treatment.
Data collection: Data were collected on recruitment and
subsequently at six and eight months of pregnancy and at
two and six months post partum. Gestational age was
determined by obstetric evaluation. Where this was not
possible, antenatal ultrasonography by a portable system was
used (Philips, Netherlands). Blood was drawn into EDTA-
vacutainer tubes at every visit. Data collected included:
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maternal age, complete blood count, gestational age, complete
blood count, HIV diagnosis, 3-monthly CD4+ T cell counts,
infant polymerase chain reaction (PCR) for HIV-DNA and
HIV antibody test.
Data analysis: Data were managed and analysed by
Statview Software (Abacus Concepts, Inc., Berkeley, CA,
USA). Nominal/ discrete variables were analysed using Chi-
square tests with Fisher’s exact test to determine significance.
RESULTS
Sample size: Out of 107 mothers who tested HIV
seropositive and were thus eligible for the present
Table 1





<19 6 0 6
19-24 21 4 17
25-29 10 2 8
30-34 5 1 4
35-39 1 0 1
>40 1 0 1
Missing 15 5 10
Mean Parity 2 2 3
Gestation age at birth
(weeks)
Full term (37-40) 30 3 27
Pre-term (<37) 7 2 5
Missing 12 12 8
Baby status
Alive 38 2 36
Dead 15 6 9
Still Birth 1 1 0
Missing 5 3 2
Birth Outcome
Boy 25 6 19
Girl 34 6 28
Boy/Boy 0 0 0
Girl/Girl 0 0 0
Boy/Girl 0 0 0
Baseline (CD4+µl)
*Class 1 (>500) 21 4 17
*Class 2 (200- 499)18 2 16
*Class 3 (<200) 4 1 3
Not Done 17 5 11
Place of Delivery
Health Centre 15 2 13
Hospital 8 3 5
Home 30 6 24
Missing 6 1 5
Mode of Delivery
Vaginal 54 12 42
Caesarean Section 0 0 0
Missing 5 0 5
y Transmitters are mothers who infected their children with HIV-1.
f Non-transmitters are mothers who did not transfer HIV-1 infection
to their children. * Classes 1-3 are CDC immunological categories
based on CD4+ T cell counts (Centres for Diseases Control and
Prevention (CDC). Revised Guidelines for Performing CD4+ T cell
determinations in persons infected with human immunodeficiency
virus, MMWR, 1997; 46 (RR-2): 1-29).
study, only 59 (55%) successfully completed the study.
The rest were excluded from the present analysis for
various reasons: eight (7.5%) died in the course of the
study, 15 (14%) lost sick baby after illness and declined
further participation in the study, 18 (17%) refused to
have blood drawn and seven (6.5%) were lost to follow-
up.
Characteristics of participating women: Table 1
shows characteristics of mothers tudied stratified by
Figure 1
Results of testing peripheral blood mononuclear cells
(PBMC) DNA from children born to HIV infected
mothers with four sets of nested primers. Track 17 is
positive control sample from a known PCR positive
mother amplifying all primers (note that the same sample
is in track 14 on POL). Tracks 2,12, and 16 are
consistently PCR negative samples from children born to
HIV positive mothers. Most PCR positive samples
amplified ENV and POL primers (tracks 5,6,13,15).
Track 5 is one of the few samples amplifying all HIV
primers in use. Track is molecular weight marker. Beta-
microglobulin PCR was initially performed to test
quantity of DNA extracts of each specimen
the HIV status of their index child. There were no
statistically significant differences between the
transmitter and non-transmitter mothers with regard to;
age, parity, age at birth and birth outcome and socio-
economic status. The majority (51%) of mothers
delivered between 38-40 weeks of gestation and at
home. Mothers with no education were more likely to
have their first-born deliveries at (p=0.018). Most of
the mothers who delivered at home had educational
level ranging from nil to upper primary.
M ther-to child transmission of HIV-1 rate: The
number of children with positive PCR (Figure 1) of
consecutively processed samples under nine months,
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antibody particle agglutination (PA) test were 12 out
of 59. This represented a vertical transmission rate of
20.3%.
Effect of AZT on CD4 T cell levels: The profiles
of CD4+ T cell counts harvested at week 24 of
gestation, through pregnancy to 10 weeks after delivery
are illustrated in Figure 2. When the profiles were
stratified by the HIV infection status of the child, it
was clear that there was an increase of CD4+ T cells
in all mothers following AZT therapy. Paired comparison
of CD4+ T cell changes at different stages showed that
the increase was more significant between week 34 of
gestation and 10 weeks after delivery (p=0.01) for all
moth rs. The results also showed a more enhanced
increase of CD4+ T cells in mothers who did not
eventually transmit he HIV virus to their infants.
Figure 2
Absolute CD4+ cell counts (cells/microlitre) and 95% confidence intervals at specified times before and after AZT
prophylaxis for HIV transmitter and non-transmitter mothers
Figure 3
Absolute CD4+ cell changes and 95% confidence intervals at 2 points: between 34 weeks of gestation (just before
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AZT-associated CD4+ changes: Paired t-test was
used to compare the specific CD4+ T cell increases
in the two categories of mothers (transmitters and non-
transmitters of HIV) before and after AZT administration.
The increase in CD4+ T cell counts was significantly
associated with lack of transmission of HIV-1
(p=0. 0135) (Figure 3).
DISCUSSION
Out of 107 HIV-seropositive pregnant women
enrolled in the study, only 59 were selected for the
present analysis. These were mothers who had not only,
completed the full dose of antenatal AZT, but also had
consistent evaluations from recruitment hrough
pregnancy and after delivery. Since repeated
measurements were to be used in the analysis, the use
of consistently collected data during the study period
helped minimise potential bias. In addition, these
mothers were selected because they consented to having
their infants bled consecutively for virological assays.
We used absolute CD4+ T cell and not the percent
CD4+ counts as a measure of immune status. This is
because in our experience, alterations in maternal blood
volume (haemodilution) in pregnancy and delivery did
not significantly alter the absolute counts of this cohort
(unpublished data). Also, given that CD4+ counts are
known to be subject o significant regular individual
variations, we considered overall trends in the CD4+
T cell counts which, in common experience of both
clinicians and patients, may be more meaningful than
percentage counts.
Of the 59 mothers given short course AZT
prophylaxis to prevent mother to child HIV transmission,
12(20.3%) transmitted HIV-1 to their children while
47(79.7%) did not. Without interventions the risk of
mother-to child of HIV-1 in sub-Saharan Africa is
estimated to be between 25% and 45%(9). Breastfeeding
has been reported to present an additional risk of
mother to child transmission of HIV estimated at 5%
to 12%(18). In this study, although both the infant
formula supplements were recommended and counselling
against breastfeeding done, all women chose to
breastfeed their infants due to a combination of strong
traditional attitudes and economic constraints favouring
breastfeeding (unpublished data). Additionally, our study
was based in a rural setting, where the absence of safe
alternatives to breastfeeding makes the latter the most
established and accepted method of infant feeding.
Considering that our cohort of women were derived
from a small sample size and allowed to breastfeed their
infants, the vertical infection rate of 20.3% compares
with previously reported MTCT rates of 12.2% and
15.7% at ages three weeks and four months respectively
in breastfeeding population(19). Although, the efficacy
of AZT prophylaxis in a breastfeeding population in
west Africa has been reported(15) one cannot be certain
that infection could have been prevented in additional
15% of the children whose mothers had been discouraged
from breastfeeding. This is because, the effects of
differe t infant feeding options and their duration on
he post-natal exposure to HIV-1 even during ARV is
still not well understood(20). Other risk factors known
to favour vertical transmission during AZT prophylaxis
have been identified, including infant birth weight
during study period, maternal HIV viral load, antepartum
procedures and cervicovaginal secretions(21). In this
study, these factors were not controlled for. This was
because such factors were not within the study objectives
and also because this study was situated in the rural
area where such procedures could not be undertaken
with ease.
Our results demonstrate a trend towards immune
reconstitution following AZT prophylaxis (Figure 2).
Considering that most of the participants in this study
were asymptomatic, meaning early HIV disease, this
numeric reconstitution of CD4+ T cells was
expected(22). At this stage, the mechanisms of CD4+
T lymphocytes are still functional as a result of which
antiretroviral intervention is expected to achieve
maximum suppression of HIV replication. Thus, the
immune system is expected to benefit from antiretroviral
treatment more during the asymptomatic HIV infection
than it does in late-stage disease, by which time
significant immune damage has already occurred.
From these results, it can be inferred that the
CD4+ T lymphocyte increase was in response to AZT
prophylaxis. Additionally, the observed CD4+ T cell
incre se would be expected to provide “help” for the
suppression of HIV replication thus leading to the
observed reduced risk of HIV transmission from mother
to child among the non-transmitters. However, our
findings raise two significant issues which may limit
the generalisability and interpretations of the results;
was the reduced risk of transmission of HIV-1 among
th  no -transmitter mothers a function of a rise in
CD4+ T cell only or was AZT administered at a
gestation age where restoration of CD4+ T cell levels
was more and hence risk of transmission lowest?
A multivariate analysis adjusting for maternal
CD4+ T cell counts would probably have provided
answers to the above questions. Our failure to control
for the CD4+ T cell counts in the two groups of mothers
is one of the limitations of this study. However, by
the tim  of the study, strong and statistically significant
protective ffects of AZT against MTCT even after
adjustment for maternal CD4+ T cell levels had already
been well described(16). We also took cognisance of
the earlier reports which had adjusted for CD4+ T cell
count changes over the entire period of pregnancy.
During such a long time of observation, the like-hood
tha  the effects and causes of immunosuppression due
to HIV-1 infection and pregnancy would confound
CD4+ T cell changes due AZT is expected to be higher.
In this study therefore, we decided to study changes
in CD4+ T cell counts examined immediately before
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and after AZT short-course therapy.
Although the numerical and phenotypic profiles of
the CD4+ T cell are the most widely used marker of
immune status during HIV infection, these profiles only
reflect one aspect of immune system and T cell
competence. The CD4+ T cells functions are very broad
and can only be adequately assessed through their
helper functions in terms of proliferation and alteration
in the naive and memory subsets(23) and elaboration
of cytokines that affect the entire immune system.
Because of our study design, these functional assays
of T cells were not performed. Instead we sought to
evaluate the effect of short-term AZT on CD4+ T cells
during late pregnancy in relation to transmission of
HIV-1 to infant. We acknowledge the constrained
interpretation f our findings given the small sample
size. However, our observed significant association
between prenatal use of AZT and increase in CD4+
T cell counts in non-transmitting mothers further
corroborates the previous findings(13,24) and supports
initiation of bigger cohort studies to identify the T cell
subsets and their cytokines associated with ARV
prophylaxis against MTCT. Already, a preferential loss
of naive T cells (CD45 RA+) coupled with a relative
increase in memory T cells (CD45RO+) during HIV
disease progression has been reported(22). Clearly, any
interventions that invoke the regeneration and activation
of CD4+ T cell of naive phenotype should be a major
goal of pMTCT of HIV-1 trials.
Decreased maternal CD4+ T cells have been
correlated with risk of mother to child transmission of
HIV-1(25). In this cohort the mothers did not differ
significantly with regard to CD4+ T cell counts at
baseline. Although the CD4+ T cell counts were low
at baseline in both groups of mothers, they increased
significantly more, between gestation week 36 and
delivery among the HIV-non-transmitting than the
transmitting mothers. This observation implies that
further trials on the timing of short-course regimens of
ARV against MTCT are still needed.
In conclusion these data suggest that a rise in the
CD4+ T cell counts following short AZT regimen, now
widely used in resource-weak countries, may be evidence
of the active suppression of the replication of HIV.
However, further studies to examine the multifactorial
effect of CD4+ lymphocytes and pregnancy on MTCT
of HIV need to be carried out to help fully explain
the effect of AZT, and possibly other new ARVs, on
immune response and whether the CD4+T cell count
can be used as a true and more rapid test of
immunological normalisation during intervention against
MTCT.
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